Based on genetic studies we know microbial signaling molecules control development of arthritis, uveitis and spondyloarthritis in humans. Our lab is interested in understanding this intersection between microbes and autoimmunity as a means to learn more about the pathogenesis of inflammatory diseases and contribute novel drug targets for future therapies. To learn more about how we are asking these questions see the Napier lab projects!
Follow the Napier Lab on Twitter @RuthJeanNapier
Help discover targets to treat children and adults living with Blau Syndrome.
Napier Lab news
Dr. Napier was awarded the Bruckel Early Career Investigator Award - in AxSpA" through the Spondyloarthritis Association of America
The Napier lab's research was beautifully put in an article published in OHSU Research news - Thank you OHSU!!
Dr. Napier received funding from the Arthritis National Research Foundation (ANRF) to study the CARD9/neutrophil/Th17 axis in Ankylosing Spondylitis!
The Napier lab will begin studying the role of neutrophils in Axial Spondyloarthritis thank you to funding through the Spondyloarthritis Treatment and Research Network (SPARTAN)
Napier and Rosenzweig Lab publish their findings in Nature Communications!
Dr. Napier spoke about her latest NOD2 research as it pertains to human disease at the “Inaugural Cure Blau Syndrome Research Symposium”.
The Napier Lab’s research on the Card9/neutrophil axis in arthritis and spondylitis was was featured at the 2020 American College of Rheumatology meeting.
Dr. Napier is featured in the powerful documentary “Rare Humans: Turning Hope into Action”.